Handk to introduce new anticancer drug

Handok Pharm says it has recently signed a licensing agreement with the U.S. based Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, to develop and market Spectrum’s novel antineoplastic agent in Korea.

Apaziquone is a drug currently being investigated for the treatment of non-muscle invasive bladder cancer. Apaziquone, an anti-cancer ...